The revised ATMP guideline on safety and efficacy follow-up and risk management has been released for a 3-month public consultation (deadline of 30th April).

EMA would be pleased to receive any HTA comments in respect of the post-authorisation safety and efficacy studies’ endpoints.

Please see the links below.

Guideline on safety and efficacy follow up RMP for ATMP: